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Introduction
The annual incidence of venous thrombosis is 0.1-0.3% per
year.1,2 Symptomatic pulmonary embolism is present in about
a third of patients with venous thrombosis.3 Deep vein
thrombosis and pulmonary embolism are generally consid-
ered to be two entities of the same disease. However, several
studies have shown that the prevalence of some risk factors
differs in patients with deep vein thrombosis compared with
those with pulmonary embolism. In 1996, it was first
described that the factor V Leiden mutation seems to be a
stronger risk factor for deep vein thrombosis than for pul-
monary embolism.4 This differential effect is known as the
“factor V Leiden paradox”5 and has been reported repeatedly.6-
10 A pathophysiological mechanism that can explain the fac-
tor V Leiden paradox is not at hand. The hypothesis that pres-
ence of factor V Leiden would often lead to fatal pulmonary
embolism, resulting in a lower number of factor V Leiden car-
riers among those surviving pulmonary embolism and there-
by explaining this paradox, has been rejected as autopsy stud-
ies have shown that among patients with fatal pulmonary
embolism, the proportion of subjects with factor V Leiden did
not differ from that in pulmonary embolism survivors or from
the general population.11,12 Another explanation could be that
clots in the venous system of the leg in factor V Leiden carri-
ers are more resistant to embolization due to a different struc-
ture,10 but then one might expect similar observations in other
thrombophilic defects as well. Whether the factor V Leiden
paradox also exists in other thrombophilic defects is largely
unknown, although one study has shown that it does not
exist in carriers of prothrombin G20210A.10
Therefore, we assessed whether the risk of deep vein
thrombosis and pulmonary embolism was different in rela-
tives with various thrombophilic defects in a cohort study of
families with thrombophilia.
Design and Methods
We pooled data of individual subjects from five large retrospective
family cohort studies with various thrombophilic index defects who
have been described previously.13-17
Between May 1998 and July 2004, first-degree relatives aged 15
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The term factor V Leiden (FVL) paradox is used to describe
the different risk of deep vein thrombosis and pulmonary
embolism that has been found in carriers of FVL. In a throm-
bophilic family-cohort, we estimated differences in absolute
risks of deep vein thrombosis and pulmonary embolism for
various thrombophilic defects. Of 2,054 relatives, 1,131
were female, 41 had pulmonary embolism and 126 deep
vein thrombosis. Annual incidence for deep vein thrombosis
in non-carriers of FVL was 0.19% (95%CI, 0.16-0.23), and
0.41% (95%CI, 0.28-0.58) in carriers; relative risk (RR) 2.1
(95%CI, 1.4-3.2). For pulmonary embolism these incidences
were similar in carriers and non-carriers 0.07%, respective-
ly; RR 1.0 (95% CI, 0.4-2.5). When co-inheritance of other
thrombophilic defects was excluded the RR for deep vein
thrombosis in FVL carriers was 7.0 (95%CI, 2.3-21.7) com-
pared to non-carriers and 2.8 (95%CI, 0.5-14.4) for pul-
monary embolism. For other thrombophilic defects no such
effect was observed. Thus the FVL paradox was confirmed
in our study. However, a similar paradox in carriers of other
thrombophilic defects was not observed.
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pulmonary embolism, paradox.
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ABSTRACT
Factor V Leiden paradox
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years or older of consecutive patients (probands) with document-
ed venous thrombosis (i.e. deep vein thrombosis or pulmonary
embolism) or any documented arterial thrombosis before the age
of 50 years, were enrolled after obtaining informed consent.
Detailed information about previous episodes of venous thrombo-
sis, exposure to exogenous risk factors for thrombosis and antico-
agulant treatment was collected by physicians at the outpatient
clinics using a validated questionnaire18 and reviewing medical
records. Clinical data was collected prior to laboratory testing.
Relatives were tested for factor V Leiden, prothrombin G20210A,
and hereditary deficiencies of antithrombin, protein C and protein
S by methods described previously.15-17 To avoid bias, probands
were excluded from the analyses. The study was approved by the
institutional review boards of the participating hospitals.
Venous thrombosis was considered established if deep vein
thrombosis was confirmed by compression ultrasound or veno -
graphy, and pulmonary embolism by ventilation/perfusion lung
scanning, spiral computed tomography or pulmonary angiogra-
phy, or when the patient had received full-dose heparin and a vita-
min K antagonist for at least three months without objective test-
ing at a time when these techniques were not yet available.
Venous thrombosis was defined as provoked if it occurred within
three months after exposure to exogenous risk factors including
surgery, trauma, immobilization for more than seven days, preg-
nancy, puerperium, use of oral contraceptives or hormonal
replacement therapy, or malignancy. In the absence of these risk
factors, venous thrombosis was classified as unprovoked. Subjects
with concomitant deep vein thrombosis and pulmonary
embolism were classified as having pulmonary embolism. 
Observation time was defined as the period from the age of 15
years until the first thrombotic episode or the end of study. End of
study was the date when clinical data and blood samples were col-
lected at the outpatient clinics. Hence, treatment and clinical out-
come were not influenced by the results of thrombophilia testing.
There was no administrative censoring. Annual incidences were
calculated by dividing the number of events by observed years.
Incidences and 95% confidence intervals (95%CI) were calculated
under the Poisson distribution assumption. When calculating the
annual incidence of deep vein thrombosis, subjects with pul-
monary embolism were censored and vice versa. To reduce the
possible difference in the prevalence of factor V Leiden and the
other thrombophilias based on relatives with concomitant pul-
monary embolism and deep vein thrombosis, an extra sensitivity
analysis was performed by censoring those relatives. To regard
heterogeneity of effects due to inclusion of family members of
probands with arterial thrombosis, another sensitivity analysis
was performed by excluding relatives of probands with arterial
thrombosis from the cohort. Venous thrombosis free survival was
analyzed by the Kaplan-Meier method. Continuous variables
were expressed as mean values and standard deviations; categori-
cal data as counts and percentages. Differences between groups
were evaluated by Student’s t-test or Mann-Whitney U test,
depending on the normality of data for continuous variables and
by Fisher’s exact test for categorical variables. A two-tailed P value
of less than 0.05 indicated statistical significance. Statistical analy-
ses were performed using SPSS software, version 16.0 (SPSS Inc.,
Chicago ILL).
Results and Discussion
Our study cohort comprised 4,128 relatives aged 15 years
or older of 606 probands. Of the relatives, 890 (22%) had
died before the start of the study. Another 924 (22%) rela-
tives did not participate because of various reasons includ-
ing refusal, inability to give informed consent, or residence
outside the Netherlands, and 260 (6%) relatives could not
be evaluated due to missing laboratory data. Forty-five per-
cent of the evaluated 2,054 relatives were male (Table 1);
mean age at enrollment was 46 years. Of the relatives with
venous thrombosis, 134 had deep vein thrombosis and 41
had pulmonary embolism, of whom 8 concomitant with
deep vein thrombosis. Mean age at onset of first venous
thrombosis was 35 years. Of relatives with deep vein
thrombosis, 52 (39%) had an unprovoked event whereas
17 (41%) of the pulmonary embolisms were unprovoked.
Heterozygosity for factor V Leiden mutation was
detected in 244 relatives, of whom 26 developed a deep
vein thrombosis and 5 pulmonary embolism as first
venous thrombosis. Of the 10 relatives who were
Table 1. Clinical characteristics of 2,054 relatives of thrombophilic families.
Total (n=2054) First venous thrombosis First venous thrombosis
= = 
proximal DVT (n=134) PE (n=41)
Women 1131 (55) 83 (62) 22 (54)
Age at enrollment 46 (15-92) 57 (28-89) 49 (16-87)
Age at onset first venous thrombosis 35 (15-84) 34 (16-73) 36 (15-84)
Idiopathic 69 (3) 52 (39) 17 (41)
Provoked by
Oral contraceptives 28 (1) 20 (15) 8(20)
Pregnancy/puerperium 28 (1) 24 (18) 4 (10)
Surgery, trauma, immobilization 49 (2) 37 (28) 12 (29)
Malignancy 1 (0) 1 (1) 0 (0)
Prevalence thrombophilic defects *
Antithrombin deficiency 59 (3) 18 (13) 7 (17)
Protein C deficiency 81 (4) 22 (16) 5 (12)
Protein S deficiency 83 (4) 20 (15) 7 (17)
Factor V Leiden 254 (12) 29 (22) 5 (12)
Prothrombin G20210A 255 (12) 19 (14) 5 (12)
Continuous variables denoted as median (range), categorical variables as number (%). *Numbers of relatives tested were for antithrombin 2,050, for protein C deficiency 1,997, 
for protein S deficiency 2,003 and for prothrombin G20210A-mutation 2,052, respectively.
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homozygous for this mutation, 3 developed deep vein
thrombosis and none pulmonary embolism.
Annual incidence for deep vein thrombosis in non-car-
riers of factor V Leiden was 0.19% (95%CI, 0.19-0.23),
and 0.41% (95%CI, 0.28-0.58) in carriers of the muta-
tion; relative risk 2.1 (95%CI, 1.4-3.2) (Table 2). For pul-
monary embolism, these incidences were 0.07%
(95%CI, 0.05-0.09), and 0.07% (95%CI, 0.02-0.15),
respectively; relative risk 1.0 (95%CI, 0.4-2.5). When co-
inheritance of other thrombophilic defects was exclud-
ed, the RR for deep vein thrombosis in factor V Leiden
carriers was 7.0 (95%CI, 2.3-21.7) compared to non-car-
riers and 2.8 (95%CI, 0.5-14.4) for pulmonary
embolism. Relative risks for deep vein thrombosis in
antithrombin, protein C or protein S deficient relatives
and prothrombin G20210A carriers were 7.2 (95%CI,
4.4-11.9), 6.4 (95%CI, 4.0-10.2), 7.3 (95%CI, 4.5-11.9),
and 1.3 (95% CI, 0.8-2.0), respectively, compared to
their reference groups. Relatives risks for pulmonary
embolism and their 95%CIs in these relatives were sim-
ilar to deep vein thrombosis relative risk estimates. Extra
sensitivity analysis censoring relatives with concomitant
pulmonary embolism and deep vein thrombosis did not
change outcomes (data not shown). Neither did exclusion
of all relatives (n=334) of probands (n=106) with arterial
thrombosis change outcomes.
We observed the factor V Leiden paradox which has
been described elsewhere4-10 in our population as well. As
to the suggestion of different clot-structure in persons car-
rying factor V Leiden, which could be supposed to be due
to activated protein C resistance, one would expect to also
find it in other thrombophilic defects influencing activat-
ed protein C, like protein S deficiency for example. Still,
with no other thrombophilic defect a paradox similar to
that observed in relatives with factor V Leiden was seen.
Therefore, we have found no leads in this study that could
explain why the factor V Leiden paradox exists.
Some aspects of our study warrant comment. The
strength of our study is the large number of subjects eval-
uated and the possibility of comparing a factor V Leiden
paradox effect with the effect of other thrombophilic
defects. A weakness of our study is its retrospective design
and that despite this large cohort, especially the number of
relatives with pulmonary embolism was quite low. A
proper multivariate analysis taking confounders into
account when calculating relative risk estimates was not
feasible due to these small numbers. Another possibility
that could explain the factor V Leiden paradox is if
patients with deep vein thrombosis are underdiagnosed
with pulmonary embolism. In fact, it is known that
approximately 70% of subjects with acute deep vein
thrombosis have perfusion lung scans with signs of pul-
monary embolism.19 However, it is unlikely that this
explains the factor V Leiden paradox in our cohort, as it
was not found for one of the other thrombophilias.
We conclude that in our thrombophilic family-cohort,
the factor V Leiden paradox is present in relatives carrying
factor V Leiden without evidence for a similar paradox in
carriers of other thrombophilic defects. 
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Table 2. Annual incidences of deep vein thrombosis and pulmonary embolism in relatives of probands with a thrombophilic defect.
Observation Relatives Annual Relative risk Relative risk
years* with incidence, % (95% CI) (95% CI)†
event (95% CI)
Deep vein thrombosis
No factor V Leiden (n=1800) 53829 103 0.19 (0.16-0.23) Reference Reference
Factor V Leiden (n=254) 7651 31 0.41 (0.28-0.58) 2.1 (1.4-3.2) 2.1 (1.4-3.2)
No AT deficiency (n=1991) 59959 108 0.18 (0.15-0.22) Reference Reference
AT deficiency (n=59) 1386 18 1.30 (0.77-2.05) 7.2 (4.4-11.9) 6.2 (3.8-10.2)
No Prot. C deficiency (n=1916) 57180 95 0.17 (0.14-0.20) Reference Reference
Prot. C deficiency (n=81) 2062 22 1.07 (0.67-1.62) 6.4 (4.0-10.2) 5.7 (3.6-9.1)
No Prot. S deficiency (n=1920) 57777 97 0.17 (0.14-0.20) Reference Reference
Prot. S deficiency (n=83) 1623 20 1.23 (0.75-1.90) 7.3 (4.5-11.9) 6.5 (4.0-10.6)
No G20210A-mutation (n=1792) 53798 107 0.20 (0.16-0.24) Reference Reference
G20210A-mutation (n=260) 7642 19 0.25 (0.15-0.39) 1.3 (0.8-2.0) 1.3 (0.8-2.1)
Pulmonary embolism
No factor V Leiden (n=1800) 53829 36 0.07 (0.05-0.09) Reference Reference
Factor V Leiden (n=254) 7651 5 0.07 (0.02-0.15) 1.0 (0.4-2.5) 0.6 (0.2-2.0)
No AT deficiency (n=1991) 59959 34 0.06 (0.04-0.08) Reference Reference
AT deficiency (n=59) 1386 7 0.51 (0.20-1.04) 8.9 (3.9-20.1) 8.7 (3.8-20.0)
No Prot. C deficiency (n=1916) 57180 29 0.05 (0.03-0.07) Reference Reference
Prot. C deficiency (n=81) 2062 5 0.24 (0.08-0.57) 4.8 (1.9-12.4) 5.0 (1.9-13.0)
No Prot. S deficiency (n=1920) 57777 27 0.05 (0.03-0.07) Reference Reference
Prot. S deficiency (n=83) 1623 7 0.43 (0.17-0.89) 9.2 (4.0-21.2) 9.7 (4.2-22.8)
No G20210A-mutation (n=1792) 53798 36 0.07 (0.05-0.09) Reference Reference
G20210A-mutation (n=260) 7642 5 0.07 (0.02-0.15) 1.0 (0.4-2.5) 0.7 (0.2-2.1)
* When analyzing deep vein thrombosis free survival, relatives with pulmonary embolism were censored and vice versa.†Analysis after exclusion of relatives of probands 
with arterial thrombosis. AT denotes antithrombin, Prot. C denotes protein C and Prot. S denotes protein S. 
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